ERN-LUNG is a patient-centric network of European healthcare providers and patient organisations, committed Europe-wide and globally to reducing morbidity and mortality from rare lung diseases in people of all ages through patient care, advocacy, education, research and knowledge-sharing.
A non-profit project of building a clinical care network for all rare diseases of the respiratory system, ERN-LUNG has been evaluated by the European Commission and in December 2016, the European Reference Network (ERN) Board of Member States approved ERN-LUNG as one of 24 ERNs for rare diseases. ERNs are virtual cross-border healthcare networks that provide rare disease clinicians with a centralised platform across borders to share knowledge and experiences with the objectives of improving patients’ access to diagnosis, care and treatment, establishing common rare disease databases, developing clinical guidelines, thereby facilitating the mobility of expertise rather than patients themselves.
At EDENT1FI we want to assess 200,000 children across Europe and detect whether they have early stage Type 1 Diabetes and are at risk of developing symptomatic T1D. This involves screening children from the general population for biomarkers (auto-antibodies) associated with the condition. Our mission encompasses not only the early detection of T1D in children but also the provision of continuous support and education to families navigating this challenge. By equipping these families with essential knowledge and resources, our aim is to empower them to effectively manage T1D. Through our comprehensive efforts we aspire to positively impact the lives of affected families, fostering understanding and proactive care. As such, we are paving the way to arresting T1D.
Breakthrough T1D Career Development Award - Disentangling circulating non-coding RNAs complexity by tracking their expression and origin in Type 1 Diabetes (DISCO-T1D) - PROF. GUIDO SEBASTIANI